Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5986539 | 1.00 | FAAH (0.33) | FAAHTRPV1 | |
| SCHEMBL5984929 | 0.96 | FAAH (0.38) | FAAHTRPV1 | |
| SCHEMBL5986020 | 0.96 | FAAH (0.38) | FAAHTRPV1 | |
| SCHEMBL5985928 | 0.96 | FAAH (0.38) | FAAHTRPV1 | |
| SCHEMBL5985382 | 0.96 | FAAH (0.38) | FAAHTRPV1 | |
| SCHEMBL5984849 | 0.96 | FAAH (0.38) | FAAHTRPV1 | |
| SCHEMBL5985260 | 0.96 | FAAH (0.38) | FAAHTRPV1 | |
| SCHEMBL5984552 | 0.96 | FAAH (0.38) | FAAHTRPV1 | |
| SCHEMBL5984863 | 0.96 | FAAH (0.38) | FAAHTRPV1 | |
| SCHEMBL5985378 | 0.96 | FAAH (0.38) | FAAHTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023085299-A1 | CATIONIC LIPID | 武田薬品工業株式会社 | 2023-05-19 | — | — | WO | disclosed |
| US-8269038-B2 | Process for production of sulfonic acid ester | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20100041916-A1 | PROCESS FOR PRODUCTION OF SULFONIC ACID ESTER | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2010-02-18 | — | — | US | disclosed |
| EP-2067770-A1 | PROCESS FOR PRODUCTION OF SULFONIC ACID ESTER | Wako Pure Chemical Industries, Ltd. (JP) | 2009-06-10 | — | — | EP | disclosed |
| US-7018993-B2 | Antiandrogenic agent | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-03-28 | — | — | US | disclosed |
| US-20030158164-A1 | Novel antiandrogenic agent | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1304334-A1 | NOVEL ANTIANDROGENIC AGENT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-04-23 | — | — | EP | disclosed |
| EP-0839902-B1 | Microcapsules containig bleaching aids | BASF AG (DE) | 2002-12-18 | — | — | EP | disclosed |
| EP-0888436-B2 | SOLID COMPOSITION OF HETEROCYCLIC COMPOUNDS AND/OR OXIME ESTERS AND INERT POROUS CARRIER MATERIALS | BASF AG (DE) | 2002-09-18 | — | — | EP | disclosed |
| US-6451753-B2 | CYCLIC CARBAMATE, LACTONOXY OR LACTAM STRUCTURE AND/OR OXIME ESTERS AND INERT POROUS CARRIER OF GIVEN SURFACE AREA; STORAGE STABLE SOLID, FREE-FLOWING FORM | BASF AKTIENGESELLSCHAFT (DE) | 2002-09-17 | — | — | US | disclosed |
| EP-0826025-A1 | USE OF HETEROCYCLIC COMPOUNDS AS ACTIVATORS FOR INORGANIC PEROXY COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 1998-03-04 | — | — | EP | disclosed |
| WO-1997033964-A1 | SOLID COMPOSITION OF HETEROCYCLIC COMPOUNDS AND/OR OXIME ESTERS AND INERT POROUS CARRIER MATERIALS | BASF AKTIENGESELLSCHAFT (DE) | 1997-09-18 | — | — | WO | disclosed |
| US-5643931-A | ANTIDIABETIC AGENTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1997-07-01 | — | — | US | disclosed |
| WO-1997017420-A1 | USE OF OXIME ESTERS AS ACTIVATORS FOR INORGANIC PER-COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 1997-05-15 | — | — | WO | disclosed |
| WO-1996036686-A1 | USE OF HETEROCYCLIC COMPOUNDS AS ACTIVATORS FOR INORGANIC PEROXY COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 1996-11-21 | — | — | WO | disclosed |
| EP-0696585-A1 | NOVEL BISOXADIAZOLIDINE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1996-02-14 | — | — | EP | disclosed |
| US-5039674-A | Calcium antagonistics | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-08-13 | — | — | US | disclosed |
| US-4782160-A | CALCIUM RECEPTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1988-11-01 | — | — | US | disclosed |
| EP-0276552-A1 | 1,4-dihydropyridine derivatives and their production | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1988-08-03 | — | — | EP | disclosed |
| EP-0138767-A1 | Stabilized polyolefinic compounds containing hydroxylamine derivatives | CIBA-GEIGY AG (CH) | 1985-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041916-A1 | PROCESS FOR PRODUCTION OF SULFONIC ACID ESTER | SULT1A1, SULT2A1, STS | FAAH 417/4885TRPV1 1855/4885 |
| US-20030158164-A1 | Novel antiandrogenic agent | NR5A1, CYP19A1, HSD17B11 | FAAH 1409/4885TRPV1 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.